{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:15:15Z","timestamp":1781918115303,"version":"3.54.5"},"reference-count":51,"publisher":"American Academy of Insurance Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>In the United States, ovarian cancer is the second most common form of gynecologic cancer and the second leading cause of gynecologic cancer death. It is a heterogeneous disease with many different types and subtypes. The most common variety (70%-80%) is the high-grade serous epithelial tumor. A positive family history and\/or the presence of susceptibility genes (BRCA1, BRCA2, and mismatch repair genes) increase the risk for developing the disease. Due to the lack of effective screening tools, even in those with known increased risk, most ovarian cancers are diagnosed at advanced stages. Diagnosis and accurate staging usually require tissue sampling and extensive debulking surgery performed by a surgeon who specializes in gynecologic oncology. Combination chemotherapy, before or after surgery, or as primary treatment for advanced disease is commonly needed. Mortality rates vary by stage, grade, and type of tumor. For the most common histotypes, due to the presence of advanced disease at presentation in most individuals, overall death rates remain high. Survival is better with some of the less common subtypes including sex cord stromal, germ cell and borderline epithelial ovarian tumors.<\/jats:p>","DOI":"10.17849\/insm-52-3-1-10.2a","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:32:23Z","timestamp":1758501143000},"page":"191-200","source":"Crossref","is-referenced-by-count":3,"title":["Ovarian Cancer: Many Diseases Under One Name"],"prefix":"10.17849","volume":"52","author":[{"given":"Clifton P.","family":"Titcomb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7324","reference":[{"key":"i-52-3-191-ref01","article-title":"Cancer Today, International Agency for Research on Cancer, Lyon France","author":"Global Cancer Observatory","year":"2022","unstructured":"Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer, Lyon France; 2022. Accessed May 20, 2025 at https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf"},{"key":"i-52-3-191-ref02","article-title":"Cancer Stat Facts: Ovarian Cancer","author":"National Cancer Institute","unstructured":"National Cancer Institute, Cancer Stat Facts: Ovarian Cancer. Accessed May 20, 2025 at https:\/\/seer.cancer.gove\/statfacts\/html\/ovary.html"},{"key":"i-52-3-191-ref03","article-title":"Cancer Stat Facts: Ovarian Cancer","author":"National Cancer Institute","unstructured":"National Cancer Institute, Cancer Stat Facts: Ovarian Cancer. Accessed May 20, 2025 at https:\/\/seer.cancer.gove\/statfacts\/html\/uteriine.html"},{"key":"i-52-3-191-ref04","article-title":"Cancer Stat Facts: Ovarian Cancer","author":"National Cancer Institute","unstructured":"National Cancer Institute, Cancer Stat Facts: Ovarian Cancer. Accessed May 20, 2025 at https:\/\/seer.cancer.gove\/statfacts\/html\/Cervical.html"},{"key":"i-52-3-191-ref05","series-title":"AJR Am J Roentgenol","first-page":"1351","article-title":"Ovarian Cancer, the Revised Staging System, and the Role of Imaging","volume":"206","author":"Javadi","year":"2016","unstructured":"Javadi S,\nGaneshan DM,\nQayyum A, et al. Ovarian Cancer, the Revised Staging System, and the Role of Imaging. AJR Am J Roentgenol. 2016;206:1351\u20131360."},{"key":"i-52-3-191-ref06","article-title":"Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum: Histopathology","author":"Rendi","unstructured":"Rendi MH. Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum: Histopathology. In: \nGoff B,\nGarcia RL,\nDizon DS,\nChakrabarti, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on January 9, 2024 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref07","series-title":"Front Oncol","first-page":"1399979","article-title":"Ovarian Carcinosarcoma is Highly Aggressive Compared to Other Ovarian Cancer Histotypes","volume":"14","author":"McFarlane","year":"2024","unstructured":"McFarlane I,\nPorter JM,\nBrownsell E, et al. Ovarian Carcinosarcoma is Highly Aggressive Compared to Other Ovarian Cancer Histotypes. Front Oncol. 2024;14.1399979. doi: 10.3389\/fronc.2024.1399979"},{"key":"i-52-3-191-ref08","series-title":"Cancer Treat Res Commun","first-page":"100629","article-title":"Epithelial Ovarian Cancer: Review Article","volume":"33","author":"Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial Ovarian Cancer: Review Article. Cancer Treat Res Commun. 2022;33:100629. doi: 1016\/j.ctarc.2022.100629"},{"key":"i-52-3-191-ref09","series-title":"Diagnostics (Basel)","first-page":"52","article-title":"Mucinous Cancer of the Ovary: Overview and Current Status","volume":"10","author":"Babiar","year":"2020","unstructured":"Babiar A,\nGhatage P. Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics (Basel). 2020;10:52. doi: 10.3390\/diagnostics10010052"},{"key":"i-52-3-191-ref10","series-title":"Borderline Ovarian Tumors","author":"Chen","unstructured":"Chen LM,\nBerek JS. Borderline Ovarian Tumors. \nGoff B,\nDizon DS,\nChakrabarti A,\nVora SR, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on May 16, 2025 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref11","series-title":"Virchows Arch","first-page":"125","article-title":"Ovarian Borderline Tumors in the 2014 WHO Classification: Evolving Concepts and Diagnostic Criteria","volume":"470","author":"Hauptmann","year":"2017","unstructured":"Hauptmann S,\nFriedrich K,\nRedline R,\nAvril S. Ovarian Borderline Tumors in the 2014 WHO Classification: Evolving Concepts and Diagnostic Criteria. Virchows Arch. 2017;470:125\u2013142."},{"key":"i-52-3-191-ref12","series-title":"J Gynecol Oncol","first-page":"343","article-title":"Controversies in Borderline Ovarian Tumors","volume":"4","author":"Seong","year":"2015","unstructured":"Seong SJ,\nKim DH,\nKim MK,\nSong T. Controversies in Borderline Ovarian Tumors. J Gynecol Oncol. 2015;4:343\u2013349."},{"key":"i-52-3-191-ref13","article-title":"Sex-Cord-Stromal Tumors of the Ovary: Epidemiology, Clinical Features, and Diagnosis in Adults","author":"Gershenson","unstructured":"Gershenson DM. Sex-Cord-Stromal Tumors of the Ovary: Epidemiology, Clinical Features, and Diagnosis in Adults. In: \nGoff B,\nGarcia RL,\nDizon DS,\nChakrabarti,\nVora SR eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on May 22, 2025 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref14","series-title":"Int J Gynecol Cancer","first-page":"S42","article-title":"Gynecologic Cancer InterGroup (CGIG) Consensus Review for Ovarian Sex Cord Stromal Tumors","volume":"24","author":"Ray-Coquard","year":"2014","unstructured":"Ray-Coquard I,\nBrown J,\nHarter P, et al. Gynecologic Cancer InterGroup (CGIG) Consensus Review for Ovarian Sex Cord Stromal Tumors. Int J Gynecol Cancer. 2014;24:S42\u2013S47."},{"key":"i-52-3-191-ref15","article-title":"Ovarian Germ Cell Tumors: Pathology, Epidemiology, Clinical Manifestations, and Diagnosis","author":"Gershenson","unstructured":"Gershenson DM. Ovarian Germ Cell Tumors: Pathology, Epidemiology, Clinical Manifestations, and Diagnosis. In: \nGoff B,\nPappo AS,\nGarcia RL,\nChakrabarti A,\nVora SR, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on May 22, 2025 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref16","article-title":"Overview of Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum","author":"Chen","unstructured":"Chen LM,\nBerek JS. Overview of Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum. In: \nGoff B,\nDizon DS,\nChakrabarti A,\nVora SR, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on January 9, 2024 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref17","series-title":"J Med Genet","first-page":"119","article-title":"Familial Risk of Epithelial Ovarian Carcinoma After Accounting for Gynaecological Surgery: A Population-Based Study","volume":"60","author":"Barnard","year":"2023","unstructured":"Barnard ME,\nMeeks H,\nJarboe E, et al. Familial Risk of Epithelial Ovarian Carcinoma After Accounting for Gynaecological Surgery: A Population-Based Study. J Med Genet. 2023;60:119\u2013127."},{"key":"i-52-3-191-ref18","series-title":"J Clin Oncol","first-page":"2888","article-title":"Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis from the Ovarian Cancer Cohort Consortium","volume":"34","author":"Wentzensen","year":"2016","unstructured":"Wentzensen N,\nPoole EM,\nTrabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34:2888\u20132898."},{"key":"i-52-3-191-ref19","article-title":"Early Detection of Epithelial Ovarian Cancer: Role of Symptom Recognition","author":"Goff","unstructured":"Goff B. Early Detection of Epithelial Ovarian Cancer: Role of Symptom Recognition. In: \nBarbieri RL,\nChakrabarti A, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on January 9, 2024 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref020","series-title":"Life (Bael)","first-page":"1689","article-title":"Tumor Markers and Their Diagnostic Significance in Ovarian Cancer","volume":"13","author":"Matsas","year":"2023","unstructured":"Matsas A,\nStefanoudakis D,\nTroupis T, et al. Tumor Markers and Their Diagnostic Significance in Ovarian Cancer. Life (Bael). 2023;13:1689. doi: 10.3390\/life13081689"},{"key":"i-52-3-191-ref021","series-title":"Int J Mol Sci","first-page":"12041","article-title":"Molecular Biomarkers for the Early Detection of Ovarian Cancer","volume":"23","author":"Zhang","year":"2022","unstructured":"Zhang R,\nSiu MK,\nNgan H,\nChan K. Molecular Biomarkers for the Early Detection of Ovarian Cancer. Int J Mol Sci. 2022;23:12041. doi: 10.3390\/ijms231912041"},{"key":"i-52-3-191-ref022","series-title":"Med Oncol","first-page":"265","article-title":"Liquid Biopsy in Ovarian Cancer: Advantages and Limitations for Prognosis and Diagnosis","volume":"40","author":"Karimi","year":"2023","unstructured":"Karimi F,\nAzadbakht O,\nVeisi A, et al. Liquid Biopsy in Ovarian Cancer: Advantages and Limitations for Prognosis and Diagnosis. Med Oncol. 2023;40:265. doi: 10.1007\/s12032-023-02128-0"},{"key":"i-52-3-191-ref023","article-title":"Screening for Ovarian Cancer","author":"Carlson","unstructured":"Carlson K. Screening for Ovarian Cancer. \nElmore JG,\nGoff B,\nGivens J, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on January 9, 2024 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref024","article-title":"Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum: Clinical Features and Diagnosis","author":"Chen","unstructured":"Chen LM,\nBerek JS. Epithelial Carcinoma of the Ovary, Fallopian Tube, and Peritoneum: Clinical Features and Diagnosis. In: \nGoff B,\nDizon DS,\nChakrabarti A, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed in December 2023 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref025","series-title":"Lancet","first-page":"1240","article-title":"Epithelial Ovarian Cancer","volume":"393","author":"Lheureux","year":"2019","unstructured":"Lheureux S,\nGourley C,\nVergote I,\nOza A. Epithelial Ovarian Cancer. Lancet. 2019;393:1240\u20131253."},{"key":"i-52-3-191-ref026","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","unstructured":"Amin MB,\nEdge SB,\nGreene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017."},{"key":"i-52-3-191-ref027","article-title":"Treatment of Invasive Epithelial Ovarian Cancers, by Stage","author":"American Cancer Society","unstructured":"American Cancer Society. Treatment of Invasive Epithelial Ovarian Cancers, by Stage. https:\/\/www.cancer.org\/cancer\/types\/ovarian-cancer\/treating\/by-stage.html"},{"key":"i-52-3-191-ref028","series-title":"CA Cancer J Clin","first-page":"280","article-title":"Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine","volume":"69","author":"Lheureux","year":"2019","unstructured":"Lheureux S,\nBraunstein M,\nOza AM. Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine. CA Cancer J Clin. 2019;69:280\u2013304."},{"key":"i-52-3-191-ref029","series-title":"Int J Mol Sci","first-page":"1845","article-title":"Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements","volume":"25","author":"Tavares","year":"2024","unstructured":"Tavares V,\nMarques IS,\nGuerra del Melo I, et al. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements. Int J Mol Sci. 2024;25:1845. https:\/\/doi.org\/10.3390\/ijms25031845"},{"key":"i-52-3-191-ref030","article-title":"First-Line Chemotherapy for Advanced (Stage III or IV) Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer","author":"Herzog","unstructured":"Herzog TJ,\nArmstrong DK. First-Line Chemotherapy for Advanced (Stage III or IV) Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. In: \nGoff B,\nDizon DS,\nVora SR, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on January 9, 2024 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref031","article-title":"Sex-Cord-Stromal Tumors of the Ovary: Management in Adults","author":"Gershenson","unstructured":"Gershenson DM. Sex-Cord-Stromal Tumors of the Ovary: Management in Adults. In: \nGoff B,\nGarcia RL,\nDizon DS,\nChakrabarti,\nVora SR, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on May 27, 2025 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref032","article-title":"Treatment of Malignant Germ Cell Tumors of the Ovary","author":"Gershenson","unstructured":"Gershenson DM. Treatment of Malignant Germ Cell Tumors of the Ovary. In: \nGoff B,\nPappo AS,\nDizon DS,\nChakrabarti A,\nVora SR, eds. UpToDate. Waltham, MA: UpToDate Inc. Accessed on May 27, 2025 at http:\/\/www.uptodate.com"},{"key":"i-52-3-191-ref033","series-title":"J Natl Cancer Inst","first-page":"60","article-title":"Invasive Epithelial Ovarian Cancer Survival by Histiotype and Disease Stage","volume":"111","author":"Peres","year":"2019","unstructured":"Peres LC,\nCushing-Haugen KL,\nKobel M, et al. Invasive Epithelial Ovarian Cancer Survival by Histiotype and Disease Stage. J Natl Cancer Inst. 2019;111:60\u201368."},{"key":"i-52-3-191-ref034","series-title":"Gynecol Oncol","first-page":"85","article-title":"Ten-Year Conditional Probability of Survival for Patients with Ovarian Cancer: A New Metric Tailored to Long-Term Survivors","volume":"169","author":"Kahn","year":"2023","unstructured":"Kahn R,\nFilippova O,\nGordhandas S, et al. Ten-Year Conditional Probability of Survival for Patients with Ovarian Cancer: A New Metric Tailored to Long-Term Survivors. Gynecol Oncol. 2023;169:85\u201390."},{"key":"i-52-3-191-ref035","series-title":"JMIR Public Heath Surveill","first-page":"e25976","article-title":"Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database","volume":"7","author":"Yang","year":"2021","unstructured":"Yang SP,\nSu HL,\nChen XB, et al. Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database. JMIR Public Heath Surveill. 2021;7:e25976. doi: 10.2196\/25976"},{"key":"i-52-3-191-ref036","series-title":"Cancer Epidemiol","first-page":"102074","article-title":"Ovarian Cancer Survival by Stage, Histiotype, and Pre-Diagnostic Lifestyle Factors, in the Prospective UK Million Women Study","volume":"76","author":"Gaitskell","year":"2022","unstructured":"Gaitskell K,\nHermon C,\nBarnes I, et al. Ovarian Cancer Survival by Stage, Histiotype, and Pre-Diagnostic Lifestyle Factors, in the Prospective UK Million Women Study. Cancer Epidemiol. 2022;76:102074. doi: 10.1016\/j.canep.2021.102074. Epub 2021."},{"key":"i-52-3-191-ref037","series-title":"BMC Cancer","first-page":"1039","article-title":"Long-Term Mortality Among Women with Epithelial Ovarian Cancer: A Population-Based Study in British Columbia, Canada","volume":"18","author":"Arora","year":"2018","unstructured":"Arora N,\nTalhouk A,\nMcAlpine J. Long-Term Mortality Among Women with Epithelial Ovarian Cancer: A Population-Based Study in British Columbia, Canada. BMC Cancer. 2018;18:1039. doi: 10.1186\/s12885-018-4970-9. Software: Surveillance Research Program, National Cancer Institute SEER*Stat Software (www.seer.cancer.gove\/seerstat) version 8.4.5."},{"key":"i-52-3-191-ref038","article-title":"Data: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gove) SEER*Stat Research Data, 17 Registries, Nov 2023 Sub (2000-2021)-Linked to County Attributes \u2013 Time Dependent (1190-2022) Income\/Rurality, 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program","unstructured":"Data: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gove) SEER*Stat Research Data, 17 Registries, Nov 2023 Sub (2000-2021)-Linked to County Attributes \u2013 Time Dependent (1190-2022) Income\/Rurality, 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission."},{"key":"i-52-3-191-ref039","series-title":"Int J Gynecol Cancer","first-page":"926","article-title":"Non-Gestational Choriocarcinoma: Unraveling the Similarities and Distinctions from Its Gestational Counterpart","volume":"34","author":"Mangia","year":"2024","unstructured":"Mangia M,\nPalo S,\nKanikaram P,\nKaur H. Non-Gestational Choriocarcinoma: Unraveling the Similarities and Distinctions from Its Gestational Counterpart. Int J Gynecol Cancer. 2024;34:926\u2013934. doi: 10.1136\/ijgc-2023-004906"},{"key":"i-52-3-191-ref040","series-title":"J Ovarian Res","first-page":"56","article-title":"A Poor Prognostic Nongestational Choriocarcinoma of the Ovary: A Case Report and the Literature Review","volume":"14","author":"Nishino","year":"2021","unstructured":"Nishino K,\nYamamoto E. A Poor Prognostic Nongestational Choriocarcinoma of the Ovary: A Case Report and the Literature Review. J Ovarian Res. 2021;14:56. https:\/\/doi.org\/10.1186\/s13048-021-00810-3"},{"key":"i-52-3-191-ref041","series-title":"Arch Gynecol Obstet","first-page":"901","article-title":"Clinicopathological Factors and Prognosis Analysis of 39 Cases of Non-Gestational Ovarian Choriocarcinoma","volume":"301","author":"Liu","year":"2020","unstructured":"Liu X,\nZhang X,\nPang Y, et al. Clinicopathological Factors and Prognosis Analysis of 39 Cases of Non-Gestational Ovarian Choriocarcinoma. Arch Gynecol Obstet. 2020;301:901\u2013912."},{"key":"i-52-3-191-ref042","series-title":"Diagnostics","first-page":"560","article-title":"Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype","volume":"12","author":"Cronin","year":"2022","unstructured":"Cronin S,\nAhmed N,\nCraig A, et al. Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype. Diagnostics. 2022;12:560. https:\/\/doi.org\/10.3390\/diagnostics12030560"},{"key":"i-52-3-191-ref043","series-title":"Anticancer Res","first-page":"6725","article-title":"Long-Term Follow-Up of Borderline Ovarian Tumors Clinical Outcome and Prognostic Factors","volume":"34","author":"Lazarou","year":"2014","unstructured":"Lazarou A,\nFotopoulou C,\nCoumbos A, et al. Long-Term Follow-Up of Borderline Ovarian Tumors Clinical Outcome and Prognostic Factors. Anticancer Res. 2014;34:6725\u20136730."},{"key":"i-52-3-191-ref044","series-title":"Gynecol Oncol","first-page":"267","article-title":"A Nationwide Study of Serous \u201cBorderline\u201d Tumors in Denmark 1978-2002: Centralized Pathology Review and Overall Survival Compared with the General Population","volume":"134","author":"Hannibal","year":"2014","unstructured":"Hannibal CG,\nVang R,\nJung G, et al. A Nationwide Study of Serous \u201cBorderline\u201d Tumors in Denmark 1978-2002: Centralized Pathology Review and Overall Survival Compared with the General Population. Gynecol Oncol. 2014;134:267\u2013273."},{"key":"i-52-3-191-ref045","series-title":"Cancer. Cancer","first-page":"1045","article-title":"Survival Among Women with Borderline Ovarian Tumors and Ovarian","volume":"100","author":"Sherman","year":"2004","unstructured":"Sherman ME,\nMink PJ,\nCurtis R, et al. Survival Among Women with Borderline Ovarian Tumors and Ovarian Cancer. Cancer. 2004;100:1045\u20131052."},{"key":"i-52-3-191-ref046","series-title":"Gynecol Oncol","first-page":"34","article-title":"Long-Term Survival and Patterns of Care in Women with Ovarian Tumors of Low Malignant Potential","volume":"86","author":"Trimble","year":"2002","unstructured":"Trimble CL,\nKosary C,\nTrimble EL. Long-Term Survival and Patterns of Care in Women with Ovarian Tumors of Low Malignant Potential. Gynecol Oncol. 2002;86:34\u201337."},{"key":"i-52-3-191-ref047","series-title":"Acta Obstet Gynecol Scand","first-page":"473","article-title":"Long-Term Survival in Women with Borderline Ovarian Tumors: A Population-Based Survey of Borderline Ovarian Tumors in Sweden","volume":"95","author":"Kalapotharakos","year":"1960\u20132007","unstructured":"Kalapotharakos G,\nHoberg T,\nMuangmool T, et al. Long-Term Survival in Women with Borderline Ovarian Tumors: A Population-Based Survey of Borderline Ovarian Tumors in Sweden 1960\u20132007. Acta Obstet Gynecol Scand. 2016;95:473\u2013479."},{"key":"i-52-3-191-ref048","series-title":"Asian Pac J Cancer Care","first-page":"249","article-title":"Survival Outcomes and Prognostic Factors of Borderline Ovarian Tumors","volume":"6","author":"Phansence","year":"2021","unstructured":"Phansence S,\nTantipalkorn C, et al. Survival Outcomes and Prognostic Factors of Borderline Ovarian Tumors. Asian Pac J Cancer Care. 2021;6:249\u2013255."},{"key":"i-52-3-191-ref049","series-title":"Int J Gynecol Obstet","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.5772\/intechopen.107755","article-title":"Do Survivors of Borderline Ovarian Tumors Have a Susceptibility to Secondary Primary Malignancies? A SEER Population Study","volume":"165","author":"Wang","year":"2024","unstructured":"Wang J,\nDu Y,\nKang Y. Do Survivors of Borderline Ovarian Tumors Have a Susceptibility to Secondary Primary Malignancies? A SEER Population Study. Int J Gynecol Obstet. 2024;165:1229\u20131236."},{"key":"i-52-3-191-ref50","series-title":"Int J Cancer","first-page":"1370","article-title":"Risk of Nonovarian Cancer in Nationwide-Based Study of Nearly 5000 Women with Borderline Ovarian Tumors in Denmark","volume":"152","author":"Hannibal","year":"2023","unstructured":"Hannibal CG,\nBaandrup L,\nHertzum-Larsen R, et al. Risk of Nonovarian Cancer in Nationwide-Based Study of Nearly 5000 Women with Borderline Ovarian Tumors in Denmark. Int J Cancer. 2023;152:1370\u20131377."},{"key":"i-52-3-191-ref51","series-title":"Mol Clin Oncol","first-page":"1323","article-title":"Clinical Characteristics and Prognostic Analysis of Krukenberg Tumor","volume":"3","author":"Wu","year":"2015","unstructured":"Wu F,\nZhao X,\nBiabing Mi, et al. Clinical Characteristics and Prognostic Analysis of Krukenberg Tumor. Mol Clin Oncol. 2015;3:1323\u20131328."}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/52\/3\/article-p191.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/52\/3\/article-p191.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/52\/3\/article-p191.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:14Z","timestamp":1760144234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/52\/3\/article-p191.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":51,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.17849\/insm-52-3-1-10.2a","relation":{},"ISSN":["0743-6661"],"issn-type":[{"value":"0743-6661","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}